wearable Archives - Medical Design Sourcing

FDA clears Masimo W1 medical watch

The Masimo W1 medical watch [Image courtesy of Masimo]Masimo (NASDAQ: MASI) + has received FDA 510(k) clearance for its medical watch for both over-the-counter and prescription use.

The FDA clearance is the latest good news for Masimo, which has been making headway in its patent battle with tech giant Apple. MASI shares were up more than 1% to $94.75 apiece by midday trading today on the news, which came out on the evening of Friday, Nov. 17. MassDevice‘s MedTech 100 Index is up slightly.

According to the company, the Masimo W1 is the first FDA-cleared watch capable of continuously monitoring real-time oxygen saturation (SpO2) and pulse rate for both general and medical use. The FDA’s clearance enables people to use the watch in hospitals, clinics, long-term care facilities, at home, and more.

“Clinicians at numerous prestigious institutions in Europe and the Middle East are already using Masimo W1 in…

Scientists report wearable breakthrough in electric control of DNA

In what they believe is a wearable breakthrough, researchers stimulated engineered cells to control insulin expression in mice. [Illustration by Nathan Devery via Adobe Stock]

Researchers at ETH Zurich in Switzerland say they’ve made a wearable breakthrough, developing an electrogenetic interface to enable transgene expression in human cells.

They call their work DART, for direct current (DC)-actuated regulation technology. It uses power “to generate non-toxic levels of reactive oxygen species that act via a biosensor to reversibly fine-tune synthetic promoters,” they said in a paper published in Nature Metabolism.

“We designed an electrogenetic interface consisting of genetic components that render human cells responsive to DC-triggered electrostimulation and enable exclusive, DC-adjustable transgene expression,” the researcher said.

The researchers bel…

Abbott CEO touts future of biowearables in first-ever healthcare company keynote at CES

Eliud Kipchoge is training with Abbott’s Libre Sense to monitor his glucose levels to help him achieve optimal athletic performance.

Abbott (NYSE:ABT) Chairman & CEO Robert B. Ford highlighted what the future holds as he presented the first healthcare keynote ever at CES.

Speaking at the Consumer Electronics Show (CES) 2022 event, Ford headlined the “Human-Powered Health: Unlocking the Possibility of You” event, announcing that Abbott is developing a new category of biowearables called “Lingo.”

“Technology gives us the power to digitize, decentralize and democratize healthcare, create a shared language between you and your doctor – and put more control of your health in your hands,” Ford said. “We’re creating a future that will bring you and your loved ones care that’s more personal and precise. It’s happening right now. And its potential is no less than incredible.”

Abbott Park,…

AFYX Therapeutics touts study results for biodegradable oral adhesive patch

AFYX Therapeutics announced today that a study observed successful transmucosal delivery of a corticosteroid with its Rivelin patch.

The Rivelin clobetasol patch (Rivelin-CLO) is a novel adhesive patch designed to deliver a therapeutic agent to wet tissue surfaces. The study, published in The European Journal of Oral Sciences, was the first to show the successful transmucosal delivery of the corticosteroid using electrospun patch technology, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Wearable infusion device maker Bexson Biomedical appoints senior VP of drug delivery

Bexson Biomedical announced today that it appointed Sheldon Moberg as its new senior vice president of drug delivery.

Santa Barbara, Calif.-based Bexson said in a news release that Moberg will lead the development of its drug delivery technologies, starting with a wearable infusion device for its BB106 therapy developed in partnership with Stevanato Group.

Get the full story at our sister site, Drug Delivery Business News.

Philips launches new face scanning tech, partners with BioIntelliSense on telehealth

Royal Philips (NYSE:PHG) today announced two separate steps toward helping patients receive remote care as telehealth’s importance continues to grow.

Amsterdam-based Philips said today that it launched its Philips Respironics mask selector 3D facial scanning system for fitting masks and formed a strategic collaboration with BioIntelliSense to monitor at-risk patients from the hospital into the home.

The company touts its Respironics mask selector as the first and only clinically validated solution of its kind, as it helps providers fit nine of 10 patients with the right mask from the start, offering help in the shift toward digitized healthcare and reduced costs associated with fitting time and mask waste.

Using 3D camera technology, scans with the system capture 150 frames and 15 million points of facial geography data. Philips’ algorithm identifies the 46,200 data points most critical to providing an accurate and precise mask recommendation…